Management of pulmonary involvement in children with cystic fibrosis;Prise en charge de l'atteinte pulmonaire au cours de la mucoviscidose chez l'enfant

Archives de Pediatrie

Volumn 8, Issue SUPPL. 5, 2001, Pages

  Pin, I ^a   Bremont F ^b   Clement A ^c   Sardet, A ^d  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b HÔPITAL DES ENFANTS   (France)

^c ARMAND TROUSSEAU HOSPITAL   (France)

^d Centre Hospitalier de LENS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; ANTIINFLAMMATORY AGENT; AZTREONAM; BECLOMETASONE DIPROPIONATE; BRONCHODILATING AGENT; BUDESONIDE; CARBENICILLIN; CEFEPIME; CEFPIROME; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; DORNASE ALFA; FLUTICASONE PROPIONATE; GENTAMICIN; GLYPRESSINE; IMIPENEM; MEROPENEM; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; TEMOCILLIN; TERLIPRESSIN; TICARCILLIN; TIMENTIN; TOBRAMYCIN;

BRONCHUS SECRETION; CHILD; CHRONIC RESPIRATORY FAILURE; CLINICAL FEATURE; CYSTIC FIBROSIS; HEMOPTYSIS; HUMAN; KINESIOTHERAPY; LUNG DISEASE; LUNG FUNCTION; OXYGEN THERAPY; PNEUMOTHORAX; PROGNOSIS; RESPIRATORY TRACT INFECTION; REVIEW;

ADULT; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; HUMANS; INFANT; INFANT, NEWBORN; PATIENT CARE TEAM; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY THERAPY; RESPIRATORY TRACT INFECTIONS; RISK FACTORS;

EID: 0035685708     PISSN: 0929693X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (134)

1. Physiopathologie de l'atteinte pulmonaire de la mucoviscidose
2. Cystic fibrosis
3. Long term study of 105 patients with cystic fibrosis: Studies made over 5-14 year period
4. Cystic fibrosis clinical scoring systems
5. Prediction of mortality in patients with cystic fibrosis
6. A prognostic model for the prediction of survival in cystic fibrosis
7. The prognostic value of exercise testing in patients with cystic fibrosis
8. Risk of death in cystic fibrosis patients with severely compromised lung function
9. Nocturnal oxygen desaturation and spirometric parameters in adults with cystic fibrosis
10. Relationship between airway obstruction, desaturation during exercise and nocturnal hypoxemia in cystic fibrosis patients
11. The « worth » of routine spirometry in a cystic fibrosis clinic
12. The chest roentgenogram in cystic fibrosis: A new scoring system
13. The chest radiograph in cystic fibrosis: A new scoring system compared with the Chrispin-Norman and the Brasfield scores
14. The systematic evaluation of the chest radiograph in cystic fibrosis
15. High-resolution computed tomography in pulmonary cystic fibrosis
16. Cystic fibrosis scoring system with thin section CT
17. Cystic fibrosis: When should high-resolution computed tomography of the chest be obtained?
18. Cystic fibrosis in children: HRCT finding and distribution of disease
19. Cystic fibrosis: When should high-resolution computed tomography of the chest be obtained?
20. Quality of life in adults with cystic fibrosis
21. Measuring quality of life in children with cystic fibrosis: The Cystic Fibrosis Questionnaires (CFQ)
22. Microbiology of lung infection in cystic fibrosis
23. Mucoviscidose: Analyse comparative des données épidémiologiques des observatoires français et nord-américain
24. Systemic review of antistaphylococcal antibiotic therapy in cystic fibrosis
25. Microbiology of sputum from patients at cystic fibrosis centers in the United States
26. Infections pulmonaires
27. Pseudomonas cepacia infection in cystic fibrosis: An emerging problem
28. Colonization of the respiratory tract with Pseudomonas cepacia in cystic fibrosis. Risk factors and outcomes
29. Pseudomonas cepacia infection in patients with cystic fibrosis
30. Transmissibility of Pseudomonas cepacia infection in clinic patients and lung transplant recipients with cystic fibrosis
31. Evidence for transmission of Pseudomonas cepacia by social contact in cystic fibrosis
32. Effect of antibiotic treatment on inflammatory markers and lung function in cystic fibrosis patients with Pseudomonas cepacia
33. Genotypic analysis of Burkholderia cepacia isolates from 13 French cystic fibrosis centers
34. Molecular epidemiology of Burkholderia cepacia, Xanthomonas maltophilia and Alcaligenes xyloxidans in a cystic fibrosis center
35. Bacterial colonisation with Xanthomonas maltophilia - A retrospective study in a cystic fibrosis patient population
36. Risk factors for the emergence of Stenotrophomonas maltophilia in cystic fibrosis
37. Risk factors of colonization and/or infection by Stenotrophomonas maltophilia in cystic fibrosis patients
38. Clinical manifestations of exacerbations of cystic fibrosis associated with nonbacterial infections
39. Clinical significance of the recovery of Aspergillus species from the respiratory secretions of cystic fibrosis patients
40. Variability in parameters of allergic bronchopulmonary aspergillosis in patients with cystic fibrosis
41. Sensitization to Aspergillus fumigatus and lung function in children with cystic fibrosis
42. Cultures of thoracotomy specimens confirm usefulness of sputum cultures in cystic fibrosis
43. Predictive value of oropharyngeal cultures for identifying lower airway bacteria in cystic fibrosis patients
44. What is the role of upper airway bacterial cultures in patients with cystic fibrosis?
45. Use of bronchoalveolar lavage semiquantitative cultures in cystic fibrosis
46. Optimum use of selective plated media in primary processing of respiratory tract specimens from patients with cystic fibrosis
47. Improved recovery of mycobacteria from respiratory secretions of patients with cystic fibrosis
48. Non tuberculous mycobacteria in cystic fibrosis
49. Home use nebulizers: A potential primary source of Burkholderia cepacia and other colistinresistant, gram-negative bacteria in patients with cystic fibrosis
50. Nosocomial acquisition of Pseudomonas aeruginosa by cystic fibrosis patients
51. Risk of cross colonisation and infection by Pseudomonas aeruginosa in a holiday camp for cystic fibrosis patients
52. Chest physiotherapy in cystic fibrosis: Spare the hand and spoil the cough?
53. Chest physiotherapy management of patients with cystic fibrosis: A meta-analysis
54. Comparison of the flutter device to standard chest physiotherapy in hospitalized patients with cystic fibrosis
55. Evaluation of positive expiratory pressure as adjunct to chest physiotherapy in the treatment of cystic fibrosis
56. Exercise and cystic fibrosis: The search for a therapeutic optimum
57. Management of pulmonary disease in patients with cystic fibrosis
58. Quality of well-being before and after antibiotic treatment of pulmonary exacerbation in patients with cystic fibrosis
59. Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone
60. Changing susceptibility of Pseudomonas aeruginosa isolates from cystic fibrosis patients with the clinical use of newer antibiotics
61. Effects of viral low respiratory tract infection on lung function in infants with cystic fibrosis
62. Severe viral respiratory infections in infants with cystic fibrosis
63. Intravenous colistin sulphomethate in acute respiratory exacerbations in adult patients with cystic fibrosis
64. Ciprofloxacine as a therapeutic modality in pediatric burn wound infections: Efficacious or contraindicated
65. Oral ciprofloxacine in the treatment of pseudomonas exacerbations in paediatric cystic fibrosis; Clinical efficacy and safety evaluation by magnetic resonance image scanning
66. Prevention of chronic Pseudomonas aeruginosa colonization in cystic fibrosis by early treatment
67. Early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis
68. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis
69. Placebo-controlled double-blind randomized study of aerosolized tobramycin for the early treatment of Pseudomonas colonization in cystic fibrosis
70. Treatment of Staphylococcus aureus in cystic fibrosis
71. Prognosis in cystic fibrosis treated with continuous ciprofloxacin from the neonatal period
72. Pseudomonas aeruginosa infection in cystic fibrosis and its management
73. Use of antibiotics in cystic fibrosis. The Danish approach
74. Elective versus symptomatic antibiotic treatment in cystic fibrosis patients with chronic pseudomonas infection of the lungs
75. The pharmacokinetics and toxicity of once-daily tobramycine therapy in children with cystic fibrosis
76. Pharmacokinetics and bronchial diffusion of single daily dose amikacin in cystic fibrosis patients
77. Efficacy, tolerance, and pharmacokinetics of once daily tobramycin for pseudomonas exacerbations in cystic fibrosis
78. Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycine
79. Anti-inflammatory effects of macrolide antibiotics
80. Direct evidence for antipseudomonal activity of macrolides: Exposure-dependent bactericidal activity and inhibition of protein synthesis by erythromycine, clarithromycine, and azithromycine
81. Long-term azithromycin may improve lung function in children with cystic fibrosis
82. Inhalation of antibiotics in cystic fibrosis
83. Nebulized antipseudomonal antibiotic therapy in cystic fibrosis: A meta-analysis of benefits and risks
84. Aerosol carbenicillin and gentamycin treatment of Pseudomonas aeruginosa infections in patients with cystic fibrosis
85. Inhaled ceftazidim compared with carbenicillin and gentamycine in older patients with cystic fibrosis infected with Pseudomonas aeruginosa
86. Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection
87. Efficacy of aerosolized tobramycin in patients with cystic fibrosis
88. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis
89. Randomised UK/Eire clinical trial of the efficacy and safety of tobramycin nebuliser solution or nebulised colistin in CF patients
90. Etude comparative sur les performances et l'ergonomie des nébuliseurs dans la mucoviscidose
91. Aerosolized vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infection in cystic fibrosis
92. Bronchodilator response in adult patients with cystic fibrosis: Effects on large and small airways
93. Effectiveness of bronchodilators in cystic fibrosis
94. Comparison of nebulised and intravenous terbutaline during exacerbations of pulmonary infections in cystic fibrosis
95. A controlled trial of long term bronchodilator therapy in cystic fibrosis
96. Effect of aerosolized recombinant human DNAse on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis
97. DNAse trials in cystic fibrosis
98. Long term effects of aerolised rhDNase on pulmonary disease progression in patients with cystic fibrosis
99. Where we are now with rhDNase?
100. Early treatment with dornase alpha in cystic fibrosis: What are the issues?
101. Short-term efficacy of ultrasonically nebulised hypertonic saline in cystic fibrosis
102. The use of anti-inflammatory medications in cystic fibrosis
103. Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis
104. A multicenter study of alternate prednisone therapy in patients with cystic fibrosis
105. Risk of persitent growth impairment with alternate day prednisone treatment in children with cystic fibrosis
106. Controlled trial of inhaled budesonide in patients with cystic fibrosis and chronic bronchopulmonary Pseudomonas aeruginosa infection
107. Randomised controlled trial of inhaled corticosteroids (fluticasone propionate) in cystic fibrosis
108. Pilot study to assess the effect of inhaled corticosteroids on lung function in patients with cystic fibrosis
109. Effect of highdose ibuprofène in patients with cystic fibrosis
110. Oral non-steroidal anti-inflammatory drug therapy for cystic fibrosis
111. Nocturnal home oxygen in the treatment of hypoxemic cystic fibrosis
112. The effect of oxygen on sleep, blood gases and ventilation in cystic fibrosis
113. Non-invasive mechanical ventilation for cystic fibrosis patients: A potential bridge to transplantation
114. The acute effects of nasal positive pressure ventilation in patients with advanced cystic fibrosis
115. Nasal intermittent positive pressure ventilation in cystic fibrosis
116. Nocturnal ventilatory support in patients with cystic fibrosis: Comparison with supplemental oxygen
117. Longterm nasal intermittent positive pressure ventilation in patients with cystic fibrosis and hypercapnic respiratory failure
118. Nocturnal nasal IPPV stabilizes patients with cystic fibrosis and hypercapnic respiratory failure
119. Chest physiotherapy in cystic fibrosis: Improved tolerance with nasal pressure support ventilation
120. La ventilation non-invasive par masque nasal dans la mucoviscidose
121. Bronchial artery embolisation for severe hemoptysis in cystic fibrosis
122. Bronchial artery embolization for the treatment of hemoptysis in patients with cystic fibrosis
123. Treatment and prognosis of massive hemoptysis in cystic fibrosis
124. Bronchial artery embolization to control hemoptysis in cystic fibrosis
125. Five years'experience of PAS Port intravenous access system in adult cystic fibrosis
126. Pneumothorax in cystic fibrosis: A 26 year experience
127. Role of CT in the management of pneumothorax in patients with complex cystic lung disease
128. Management of pneumothorax in adult with cystic fibrosis
129. Treatment of pneumothorax in cystic fibrosis in the era of lung transplantation
130. Video-assisted thoracoscopy in the management of recurrent spontaneous pneumothorax in the pediatric population
131. Surgical management of pneumothorax in cystic fibrosis